
|Articles|November 1, 2012
Nonsurgical alternatives for treating lentigo maligna require caution
With a dearth of data regarding nonsurgical treatments for lentigo maligna (LM) and lentigo maligna melanoma (LMM), current American Academy of Dermatology guidelines advise caution regarding these therapies, said James M. Grichnik, M.D., Ph.D., at the academy's 70th annual meeting.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications
2
Recludix Pharma’s REX-8756 for Type 2 Inflammatory Diseases Enters First Human Trials
3
Alpha Tau Submits First PMA Module to FDA for Novel cSCC Treatment, Alpha DaRT
4
Oruka Reports Positive Interim Phase 1 Data for ORKA-002, Advances ORKA-001
5


















